Patent classifications
C07D277/46
TARGETED AUTOPHAGY CONJUGATES AND METHODS
Provided herein are methods and compounds for targeted autophagy.
Substituted aminothiazoles as inhibitors of nucleases
Compounds represented by the structural formula (1) R1, R2, R3, R4, R5, R6 are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
Substituted aminothiazoles as inhibitors of nucleases
Compounds represented by the structural formula (1) R1, R2, R3, R4, R5, R6 are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
Compounds and uses thereof
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
Compounds and uses thereof
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
EIF4E INHIBITORS AND USES THEREOF
The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING AZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to a pharmaceutical composition for preventing or treating cancer, wherein the pharmaceutical composition comprises a thiazole derivative or a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to a pharmaceutical composition that selectively inhibits the activity of CDK7 to reduce side effects, and treats and prevents cancer by inhibiting the proliferation of all cancer cells, rather than being limited to specific cancer cells.
INHIBITORS OF HSP70 PROTEINS
Provided are compounds useful for selectively inhibiting HSP70 isoforms. Also provided are methods of inhibiting HSP70 proteins and methods of treating a disease characterized by overexpression of a HSP70, such as cancer. In particular embodiments, the disclosed compounds may be used as potent inhibitors for HSPA5 and may display greater than 20-fold selectivity over other HSP70 isoforms.
Inhibitors of heat shock factors and uses thereof
The present disclosure relates to a class of mammalian heat shock factor (HSF) inhibitors, to pharmaceutical compositions comprising these inhibitors as well as to methods for using the inhibitors. The inhibitors inhibit stress-induced expression from heat shock gene promoters. Furthermore, the inhibitors are cytotoxic to a variety of human cancer cells types.
Inhibitors of heat shock factors and uses thereof
The present disclosure relates to a class of mammalian heat shock factor (HSF) inhibitors, to pharmaceutical compositions comprising these inhibitors as well as to methods for using the inhibitors. The inhibitors inhibit stress-induced expression from heat shock gene promoters. Furthermore, the inhibitors are cytotoxic to a variety of human cancer cells types.